Clin Oncol | Volume 1, Issue 1 | Case Report | Open Access

First Report of Propionibacterium acnes in Prostate from Chilean Patients

Catherine Sánchez1*, Hector R. Contreras2, Iván Gallegos2, Takashi Ito3, Yoshinobu Eishi3, Juan Fulla1 and Christian Ramos1

1Department of Urology, Las Condes Clinic, Chile
2Department of Urology University of Chile, Chile
3Department of Urology, Tokyo Medical and Dental University, Japan

*Correspondance to: Catherine S´┐Żnchez 

Fulltext PDF


Introduction: In prostate, inflammatory foci are usual and could be associated with chronic infections, and later with cancer development. Propionibacterium acnes were described as the most abundant bacteria in prostatic tissue and our goal was to detect it for the first time in prostate tissue samples of Chilean patients.Material and
Methods: Sixteen samples of prostate tissue from patients with cancer and benign prostatic hyperplasia were obtained from tissue bank from two clinical centers with authorization of the institutional ethics committee. Immunohistochemistry was performed to detect Propionibacterium acnes positive glands.Results: Propionibacterium acnes was detected in 7 cancer samples (100%, n=7) and 4 non cancer samples (44%, n=9). In all cancer samples, the bacteria were mainly located in non-cancerous glands (100% of patients), with low presence in cancerous glands (only 4 patients, 57.1%). Inflammatory infiltrate associated with the presence of bacteria was not significant.Conclusion: This is the first report of the presence of Propionibacterium acnes in prostate from Chilean patients. Consistent with other populations, its prevalence is high in prostate, moreover in patients with cancer, where the bacteria are located in non-tumor glands. Its presence, causing chronic infection, could have a role in prostate carcinogenesis.


Propionibacterium acnes; Prostate cancer; Prostate


Sánchez C, Contreras HR, Gallegos I, Ito T, Eishi Y, Fulla J, et al. First Report of Propionibacterium acnes in Prostate from Chilean Patients. Clin Oncol. 2016; 1: 1143.

Subscribe to Our Newsletter